Initial results from a phase III clinical trial show that simvastatin does not slow down progression in secondary progressive ...

Summary and Introduction Clinical Application—Disease Entities Theoretical Framework for Therapy−The 'Steel Paradigm' Conclusion References Theoretical Framework for Therapy−The 'Steel ...

This set consists of most of the cognate signaling intermediates (for example, STAT1 and STAT2) and was expanded to include other members of the same gene family. Human RKO cells harboring Cas9 ...

This valuable report describes the changing antiviral activity of IFIT1 across mammals and in response to distinct viruses, likely as a result of past arms races. One of the main strengths of the ...